SUN PHARMACEUTICAL INDUSTRIES LIMITED

Corporate Identity Number: L24230GJ1993PLC019050
Registered Office: Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara - 390 012, Gujarat, India.
Corporate Office: SUN House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, India.
Phone: +91 22 4324 4324 | **Fax:** +91 22 4324 4343
E-mail ID: secretarial@sunpharma.com | **Website:** www.sunpharma.com
Contact Persons: Mr. Ashok I Bhuta *(Compliance Officer)*
Mr. Sunil Ajmera *(Company Secretary & Compliance Officer)*

Corrigendum to the Public Announcement dated March 18, 2020 for the attention of the Equity Shareholders / beneficial owners of Equity Shares of Sun Pharmaceutical Industries Limited ("Company") for the buy-back of Equity Shares from the open market through stock exchanges under the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018.

This Corrigendum (**"Corrigendum"**) is in continuation of and should be read in conjunction with the public announcement dated March 18, 2020 published on March 19, 2020 in the Business Standard – English National Daily (All Editions), Business Standard - Hindi National Daily (All Editions) and Loksatta-Jansatta – Gujarati Regional Daily (Vadodara Edition) (**"Public Announcement"**) in connection with the Buy-back of Equity Shares of the Company. All the capitalized terms used herein but not defined shall have the same meaning as ascribed in the Public Announcement. The Equity Shareholders / beneficial owners of Equity Shares of the Company are requested to note the following amendment to the Public Announcement:

- Under the Paragraph 13 titled **"METHOD OF SETTLEMENT"**, in sub-paragraph 13.1 viz., Settlement of Demat Shares, the words ***"Sun Pharma-Buyback 2020-Demat A/c"*** stand substituted and should be read as ***"Sun Pharmaceutical Industries Limited-Buyback Account".***

This Corrigendum is available on the Company's website (www.sunpharma.com) and is expected to be available on the website of SEBI (www.sebi.gov.in) as well as on the website of Stock Exchanges (www.bseindia.com and www.nseindia.com).

All other information and terms of the Buy-back as disclosed in the Public Announcement shall remain unchanged.

DIRECTORS' RESPONSIBILITY STATEMENT

As per Regulation 24(i)(a) of the Buy-back Regulations, the Board accepts responsibility for the information contained in this Corrigendum and confirms that this Corrigendum contains true, factual and material information and does not contain any misleading information.

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

Sd/-	**Sd/-**	**Sd/-**
Dilip S. Shanghvi	**Sailesh T. Desai**	**Sunil R. Ajmera**
Managing Director	**Whole-time Director**	**Company Secretary**
(DIN: 00005588)	**(DIN: 00005443)**	**(Membership Number: A12176)**

Date: March 24, 2020
Place: Mumbai